
|Articles|December 25, 2021
Endocrine Month in Review: December 2021
Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, stories on the effect of delayed visits, and more.
Advertisement
Editor's note: Clicking on the center of a slide will redirect you to that story.
Top Stories of December 2021:
American Diabetes Association Releases New Standards of Care for 2022
The American Diabetes Association has released their 2022 Standards of Medical Care in Diabetes, which includes updates or additional guidance in areas such as diabetes screenings, first-line therapies, and technology use.Delayed Visits Associated with Increases in TSH Levels Among Patients Using Levothyroxine
An analysis of more than 25k patients using levothyroxine demonstrates the impact of appointment delays on TSH levels among these patients.DCRM Releases Multispecialty Guidelines for Management of Diabetes, Cardiometabolic Disease
A 31-person task force has composed and released new multispecialty recommendations for management and diagnosis of diabetes and cardiometabolic disease.Type 2 Diabetes Carries Greater Risk of Ophthalmic Complications Than Type 1 Diabetes
A Mayo Clinic-led retrospective analysis suggests patients with T2D had an 88% greater risk of developing any diabetic retinopathy within the first 15 years of diagnosis compared to those with T1D.Bariatric Surgery Associated with Lower Cancer Risk in Obesity and Diabetes
Analysis of data from the SOS study indicates bariatric surgery was associated with a 37% reduction in incident cancer among individuals with obesity and diabetes versus conventional obesity treatments, with those achieving diabetes remission experiencing a 60% reduction in risk.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
5


























































